NO834362L - Fremgangsmaate for fremstilling av svovelholdige benxylidenderivater - Google Patents
Fremgangsmaate for fremstilling av svovelholdige benxylidenderivaterInfo
- Publication number
- NO834362L NO834362L NO834362A NO834362A NO834362L NO 834362 L NO834362 L NO 834362L NO 834362 A NO834362 A NO 834362A NO 834362 A NO834362 A NO 834362A NO 834362 L NO834362 L NO 834362L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- formula
- alkyl
- derivatives
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 title claims description 3
- 229910052717 sulfur Inorganic materials 0.000 title 1
- 239000011593 sulfur Substances 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000012965 benzophenone Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000005864 Sulphur Substances 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 4
- 206010028347 Muscle twitching Diseases 0.000 description 4
- -1 alkyl radical Chemical class 0.000 description 4
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 3
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 3
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- LNAURVNIKFHZNB-UHFFFAOYSA-N (5-chloro-2-hydroxy-3-methylphenyl)-(4-chlorophenyl)methanone Chemical compound CC1=CC(Cl)=CC(C(=O)C=2C=CC(Cl)=CC=2)=C1O LNAURVNIKFHZNB-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MVQXBXLDXSQURK-UHFFFAOYSA-N 2-aminoethanesulfonamide Chemical compound NCCS(N)(=O)=O MVQXBXLDXSQURK-UHFFFAOYSA-N 0.000 description 1
- SNGRYJSFEVUFBF-UHFFFAOYSA-N 3-aminopropane-1-sulfonamide Chemical compound NCCCS(N)(=O)=O SNGRYJSFEVUFBF-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960002888 oxitriptan Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8219982A FR2536747A1 (fr) | 1982-11-29 | 1982-11-29 | Derives benzylideniques soufres, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO834362L true NO834362L (no) | 1984-05-30 |
Family
ID=9279619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO834362A NO834362L (no) | 1982-11-29 | 1983-11-28 | Fremgangsmaate for fremstilling av svovelholdige benxylidenderivater |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4521619A (sv) |
| JP (1) | JPS59108758A (sv) |
| AU (1) | AU2174683A (sv) |
| BE (1) | BE898324A (sv) |
| DE (1) | DE3342999A1 (sv) |
| DK (1) | DK544383D0 (sv) |
| ES (1) | ES8406458A1 (sv) |
| FI (1) | FI834340A (sv) |
| FR (1) | FR2536747A1 (sv) |
| GB (1) | GB2131025B (sv) |
| GR (1) | GR81260B (sv) |
| IL (1) | IL70336A0 (sv) |
| IT (1) | IT1167276B (sv) |
| LU (1) | LU85105A1 (sv) |
| NL (1) | NL8304069A (sv) |
| NO (1) | NO834362L (sv) |
| NZ (1) | NZ206410A (sv) |
| PT (1) | PT77751B (sv) |
| SE (1) | SE8305307L (sv) |
| ZA (1) | ZA838861B (sv) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE58417B1 (en) * | 1984-04-27 | 1993-09-22 | Ici Plc | Chemical derivatives |
| IT1212000B (it) * | 1987-12-24 | 1989-11-08 | Sigma Tau Ind Farmaceuti | Fenilbenziliden-derivati dell'acido 3)amminopropansolfonico ad attivita' anticonvulsivante e loro composizioni farmaceutiche per il trattamento terapeutico della epilessia |
| US6099869A (en) | 1995-04-18 | 2000-08-08 | Nutrition 21 | Calcium taurate and antihypertensive drug for hypertension |
| JP4145303B2 (ja) | 2003-04-30 | 2008-09-03 | ヒューレット−パッカード デベロップメント カンパニー エル．ピー． | ストライクプレート及びそれを利用する出口部 |
| US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| CA2900876A1 (en) | 2004-12-22 | 2006-08-17 | Bhi Limited Partnership | Methods and compositions for treating amyloid-related diseases |
| KR101443573B1 (ko) | 2006-10-12 | 2014-11-03 | 비에이치아이 리미티드 파트너쉽 | 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2120512A (en) * | 1934-04-27 | 1938-06-14 | Firm Henkel & Compagnie G M B | Sulphuric acid derivatives of organic acid amides |
| US4098900A (en) * | 1975-03-10 | 1978-07-04 | Ciba-Geigy Corporation | N,N'-Diphenyl-guanidine derivatives |
| FR2319338A1 (fr) * | 1975-08-01 | 1977-02-25 | Synthelabo | Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent |
-
1982
- 1982-11-29 FR FR8219982A patent/FR2536747A1/fr active Granted
-
1983
- 1983-09-29 SE SE8305307A patent/SE8305307L/sv not_active Application Discontinuation
- 1983-11-17 US US06/552,901 patent/US4521619A/en not_active Expired - Fee Related
- 1983-11-28 IL IL70336A patent/IL70336A0/xx unknown
- 1983-11-28 GB GB08331715A patent/GB2131025B/en not_active Expired
- 1983-11-28 PT PT77751A patent/PT77751B/pt unknown
- 1983-11-28 NL NL8304069A patent/NL8304069A/nl not_active Application Discontinuation
- 1983-11-28 JP JP58225326A patent/JPS59108758A/ja active Pending
- 1983-11-28 DK DK5443/83A patent/DK544383D0/da not_active Application Discontinuation
- 1983-11-28 ES ES527585A patent/ES8406458A1/es not_active Expired
- 1983-11-28 IT IT23925/83A patent/IT1167276B/it active
- 1983-11-28 GR GR73095A patent/GR81260B/el unknown
- 1983-11-28 LU LU85105A patent/LU85105A1/fr unknown
- 1983-11-28 NO NO834362A patent/NO834362L/no unknown
- 1983-11-28 FI FI834340A patent/FI834340A/fi not_active Application Discontinuation
- 1983-11-28 ZA ZA838861A patent/ZA838861B/xx unknown
- 1983-11-28 BE BE0/211945A patent/BE898324A/fr not_active IP Right Cessation
- 1983-11-28 DE DE19833342999 patent/DE3342999A1/de not_active Withdrawn
- 1983-11-28 NZ NZ206410A patent/NZ206410A/en unknown
- 1983-11-28 AU AU21746/83A patent/AU2174683A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT77751B (fr) | 1986-06-18 |
| ES527585A0 (es) | 1984-08-01 |
| AU2174683A (en) | 1984-06-07 |
| IT1167276B (it) | 1987-05-13 |
| ZA838861B (en) | 1984-08-29 |
| NL8304069A (nl) | 1984-06-18 |
| FI834340A (fi) | 1984-05-30 |
| ES8406458A1 (es) | 1984-08-01 |
| SE8305307D0 (sv) | 1983-09-29 |
| FI834340A0 (fi) | 1983-11-28 |
| FR2536747A1 (fr) | 1984-06-01 |
| DE3342999A1 (de) | 1984-05-30 |
| IT8323925A0 (it) | 1983-11-28 |
| IL70336A0 (en) | 1984-02-29 |
| JPS59108758A (ja) | 1984-06-23 |
| US4521619A (en) | 1985-06-04 |
| GB2131025B (en) | 1986-03-26 |
| FR2536747B1 (sv) | 1985-03-08 |
| GB2131025A (en) | 1984-06-13 |
| GR81260B (sv) | 1984-12-11 |
| SE8305307L (sv) | 1984-05-30 |
| BE898324A (fr) | 1984-05-28 |
| GB8331715D0 (en) | 1984-01-04 |
| DK544383D0 (da) | 1983-11-28 |
| NZ206410A (en) | 1986-01-24 |
| PT77751A (fr) | 1983-12-01 |
| LU85105A1 (fr) | 1985-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0683780B1 (de) | Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten | |
| DE69316067T2 (de) | Arzneimittel zur Verwendung bei der Behandlung von Parkinsonismus | |
| EP0988306A1 (de) | 3-substituierte 3,4-dihydro-thieno 2,3-d]pyrimidin-derivate, ihre herstellung und verwendung | |
| NO834362L (no) | Fremgangsmaate for fremstilling av svovelholdige benxylidenderivater | |
| DE3105858A1 (de) | "neue thieno-azepine, ihre herstellung und ihre verwendung als arzneimittel" | |
| DE2461802A1 (de) | Pyrazinderivate | |
| WO1999007711A1 (de) | 3-substituierte 3,4,5,7-tetrahydro-pyrrolo[3',4':4,5] thieno[2,3-d] pyrimidin-derivate, ihre herstellung und verwendung als 5ht-antagonisten | |
| EP1084123A1 (de) | Neue unsymmetrisch substituierte xanthin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel mit adenosinantagonistischer wirkung | |
| CA1130806A (en) | 1,2,4-oxadiazole derivatives, their preparation and pharmaceutical use | |
| EP1023296B1 (de) | 3-SUBSTITUIERTE PYRIDO 3',4':4,5] THIENO 2,3-d] PYRIMIDIN-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG | |
| EP0050212B1 (de) | 5-Substituierte 9-Cyanmethylen-dithieno(3,4-b:4'.3'-e)-azepine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel | |
| DE10236910A1 (de) | Substituierte 1,2,3,4-Tetrahydrochinolinderivate | |
| DD154487A5 (de) | Verfahren zur herstellung von 1-benzoxepin-5(2h)-on-derivaten | |
| DE3335472A1 (de) | 5h-(1)benzopyrano-(2,3,-d)pyrimidin-derivate, verfahren zu deren herstellung sowie deren verwendung bei der bekaempfung von gastralen und duodenalen schleimhautlaesionen | |
| CH617188A5 (sv) | ||
| AT390952B (de) | Verfahren zur herstellung von neuen furan- oder thiophenderivaten | |
| DE1950990A1 (de) | Verfahren zur Herstellung von neuen triazacyclischen Verbindungen | |
| EP0024560A1 (de) | Neue 3-Amino-1-benzoxepin-Derivate und ihre Salze; Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| CH617691A5 (sv) | ||
| CH511863A (de) | Verfahren zur Herstellung von 2,4-Benzdiazepinen | |
| EP1532105B1 (en) | Anthranyl derivatives having an anticholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof | |
| DE69103934T2 (de) | 4H-Pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen. | |
| AU592358B2 (en) | Derivatives of diphenoxyethylamine, a process for their production and the pharmaceutical compositions containing the same | |
| PL100617B1 (pl) | Sposob wytwarzania nowych eterowych pochodnych oksymu | |
| EP0068240A1 (de) | 2-Acylaminomethyl-1,4-benzodiazepin-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |